Kymera Therapeutics, Inc.'s Board of Directors approved an amendment to the Company's Second Amended and Restated Bylaws, effective immediately on March 25, 2026. The Bylaw Amendment designates the federal district courts of the United States as the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or their respective rules and regulations. This exclusive forum applies unless the Company provides written consent to the selection of an alternative forum. The Board's decision was made in response to recent amendments to the General Corporation Law of the State of Delaware concerning such forum selection provisions. The existing exclusive jurisdiction of the Court of Chancery of the State of Delaware for derivative actions, fiduciary duty claims, DGCL claims, and internal affairs doctrine claims remains in effect, with an explicit exclusion for federal securities claims.